Key Financial Inc’s ADMA Biologics ADMA Stock Holding History

Key Financial Inc’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-750	Closed	-$8.38K	–	1352
2024 Q2	$8.38K	Hold	750	–	–	﹤0.01%	826
2024 Q1	$4.95K	Hold	750	–	–	﹤0.01%	946
2023 Q4	$3.39K	Hold	750	–	–	﹤0.01%	1029
2023 Q3	$2.69K	Hold	750	–	–	﹤0.01%	1069
2023 Q2	$2.77K	Hold	750	–	–	﹤0.01%	1119
2023 Q1	$2.48K	Hold	750	–	–	﹤0.01%	925
2022 Q4	$1.82K	Hold	750	–	–	﹤0.01%	965
2022 Q3	$2K	Buy	+750	New	+$1.8K	﹤0.01%	922

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Key Financial Inc's ADMA Position: Q3 2024 in Review

Key Financial Inc sold out of ADMA Biologics (ADMA) in Q3 2024, closing a stake of 750 shares — an estimated $8.38K sold.

Key Financial Inc first reported a position in ADMA in Q3 2022 and held it in 8 quarters. The position peaked at $8.38K in Q2 2024. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

Key Financial Inc reported no remaining ADMA Biologics position as of Q3 2024 after selling out during the quarter.
Key Financial Inc sold 750 ADMA Biologics shares in Q3 2024, an estimated $8.38K.
Key Financial Inc first reported a position in ADMA Biologics in Q3 2022 and held it in 8 quarters.
Key Financial Inc's ADMA Biologics position peaked at $8.38K in Q2 2024.
306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Key Financial Inc's 13F filing for Q3 2024, filed 29 Oct 2024.